As diabetes is a major risk factor for CKD [67], specialized expert groups such as the Kidney Disease: Improving Global Outcomes (KDIGO) team, with the endorsement of both ADA and EASD, recommend that glycemic management for T2D patients with CKD should involve a combination of metformin and a SGLT-2 inhibitor as first-line therapy, with other drugs such as SUs considered only when additional therapies are needed for optimum glycemic control [68]
Vogel DG, Malekzadeh MH, Cornford ME, Schneider JA, Shields WD, Vinters HV (1990) Central nervous system involvement in nephropathic cystinosis
But it doesn't stop there
The connection between your digestive system, brain, and weight is stronger than you think
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function
Do not drive or operate machinery until you know how phentermine affects you